Aileron Therapeutics (ALRN)
(Real Time Quote from BATS)
$3.71 USD
+0.80 (27.49%)
Updated Sep 20, 2024 03:52 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALRN 3.71 +0.80(27.49%)
Will ALRN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALRN
Are Medical Stocks Lagging Sensus Healthcare (SRTS) This Year?
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
ALRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
Other News for ALRN
Aileron Therapeutics to Present at the 8th Annual IPF Summit
Aileron Therapeutics GAAP EPS of -$0.45
ALRN Stock Earnings: Aileron Therapeutics Misses EPS for Q2 2024
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Aileron Therapeutics reports Q2 EPS (45c), one estimate (42c)